{"id":7826,"date":"2014-04-04T14:51:36","date_gmt":"2014-04-04T14:51:36","guid":{"rendered":""},"modified":"2014-04-04T14:51:36","modified_gmt":"2014-04-04T14:51:36","slug":"tromboprofilaktika-nechirurginiams-ligoniams-profilaktinio-gydymo-mmmh-gaires","status":"publish","type":"post","link":"https:\/\/www.pasveik.lt\/lt\/naujausi-medicinos-straipsniai\/tromboprofilaktika-nechirurginiams-ligoniams-profilaktinio-gydymo-mmmh-gaires\/7826\/","title":{"rendered":"Tromboprofilaktika nechirurginiams ligoniams. Profilaktinio gydymo MMMH gair\u0117s"},"content":{"rendered":"<p class=\"Pa15\" style=\"text-align: justify;\"><strong>\u012evadas <\/strong><\/p>\n<p class=\"Pa7\" style=\"text-align: justify;\">Europoje i\u0161tyrus venini\u0173 trombini\u0173 embolij\u0173 (VTE) da\u017en\u012f hospitalizuotiems ir gydomiems am\u00adbulatori\u0161kai pacientams, nustatyta, kad per metus ji pasitaiko 148 i\u0161 100 t\u016bkst. pacient\u0173 (atitinkamai 83 atvejai hospitalizuotiems ir 65 atvejai gydomiems ambulatori\u0161kai pacientams) (1). Taip pat paai\u0161k\u0117jo, kad net 71 proc. ligonin\u0117je gydom\u0173 pacient\u0173, ku\u00adriems diagnozuota VTE, mir\u0117 (1). \u0160iuolaikiniuose medicinin\u0117s literat\u016bros \u0161altiniuose nurodoma trom\u00adboprofilaktikos nauda. Ji rekomenduojama ir prakti\u00adnio gydymo vadovuose. Ortopedijoje ir bendrojoje chirurgijoje nustatyti VTE padid\u0117jusios rizikos pe\u00adriodai ir sukurtos VTE farmakologin\u0117s profilakti\u00adkos gair\u0117s, kurios reik\u0161mingai suma\u017eino VTE rizi\u00adk\u0105 min\u0117tuose skyriuose gydomiems pacientams (2).<\/p>\n<p class=\"Pa7\" style=\"text-align: justify;\">Manoma, kad terapiniuose skyriuose hospita\u00adlizuotiems pacientams tromboprofilaktika taikoma neefektyviai (2). Taip pat paai\u0161k\u0117jo, kad terapiniuo\u00adse skyriuose gydomiems pacientams, kuriems dia\u00adgnozuota VTE, mirtin\u0173 plau\u010di\u0173 arterijos trombin\u0117s embolijos (<a href=\"https:\/\/pasveik.lt\/lt\/ligos-ir-sindromai\/pate\/43890\">PATE<\/a>) ir mirtin\u0173 arba masyvi\u0173 kraujavi\u00adm\u0173 da\u017enis yra didesnis nei chirurginiuose skyriuo\u00adse gydom\u0173 pacient\u0173, kuriems diagnozuota VTE (3). Keli\u0173 atsitiktin\u0117s imties klinikini\u0173 tyrim\u0173 rezulta\u00adtais \u012frodytas farmakologin\u0117s tromboprofilaktikos veiksmingumas ir saugumas hospitalizuotiems pa\u00adcientams (4\u20136).<\/p>\n<p class=\"Pa7\" style=\"text-align: justify;\">Daugybinius VTE rizikos veiksnius pana\u0161iai da\u017enai galima nustatyti tiek hospitalizuotiems, tiek ir ambulatori\u0161kai gydomiems pacientams (7). Daug ambulatori\u0161kai gydom\u0173 pacient\u0173, i\u0161sivys\u010dius VTE, yra hospitalizuojami (8, 9). Tromboprofilaktinio gy\u00addymo i\u0161leidus i\u0161 ligonin\u0117s nauda \u012frodyta specifin\u0117ms pacient\u0173 grup\u0117ms: vyresniems nei 75 met\u0173 pacien\u00adtams, moterims ir ne\u012fgaliesiems, kurie neatsikelia i\u0161 lovos (10). Pastaraisiais metais sukurtos skal\u0117s ir rizikos \u012fvertinimo modeliai, kurie padeda nusta\u00adtyti VTE rizik\u0105 pacientams, guldomiems \u012f ligoni\u00adn\u0119. Kai kurios skal\u0117s ir rizikos \u012fvertinimo modeliai buvo modifikuoti ir pritaikyti ambulatoriniams pa\u00adcientams (11\u201313). Atliktuose tyrimuose siekta \u012fver\u00adtinti VTE rizik\u0105 namuose gydomiems pacientams, kuriems yra suma\u017e\u0117j\u0119s mobilumas, arba sergantiems \u016bmine liga (14\u201316). Keletu tyrim\u0173 tirtas trombopro\u00adfilaktikos adekvatumas pacientams, kurie po gydy\u00admo buvo hospitalizuoti skubiosios pagalbos sky\u00adriuose (17, 18). Deja, n\u0117ra n\u0117 vieno tyrimo, kuriame b\u016bt\u0173 tirta VTE rizika terapiniams pacientams, <a href=\"https:\/\/pasveik.lt\/lt\/ligos-ir-sindromai\/pate\/43890\">pate<\/a>\u00adkusiems \u012f skubiosios pagalbos skyrius, bet nehos\u00adpitalizuotiems. Tod\u0117l atliktas tyrimas URGENTV, kurio pagrindinis tikslas \u2013 nustatyti vidutin\u0117s ir di\u00addel\u0117s VTE rizikos pacientus, i\u0161ra\u0161ytus i\u0161 skubiosios pagalbos skyri\u0173, neskiriant tolesnio adekvatus trom\u00adboprofilaktinio gydymo. Antrinis \u0161io tyrimo tikslas buvo i\u0161analizuoti veiksnius, l\u0117musius gydytojo ap\u00adsisprendim\u0105 neskirti tromboprofilaktinio gydymo, be to, nustatyti trombin\u0117s embolijos da\u017en\u012f pirm\u0105j\u012f m\u0117nes\u012f po i\u0161leidimo i\u0161 skubiosios pagalbos skyri\u0173.<\/p>\n<p class=\"Pa7\" style=\"text-align: justify;\">Straipsnyje pateikiame tyrimo URGENTV duo\u00admenis ir rezultatus (21). Jie atskleid\u017eia, kad tik ma\u00ad\u017eai daliai pacient\u0173, i\u0161leist\u0173 i\u0161 skubiosios pagalbos skyri\u0173, buvo skirtas tromboprofilaktinis gydymas, kurio nauda ir b\u016btinumas seniai \u012frodyti ir akcentuo\u00adjami \u012fvairiose gydymo gair\u0117se. Taip pat pateikta ne\u00adchirurgini\u0173 ligoni\u0173 VTE rizikos \u012fvertinimo skal\u0117 ir gydymo MMMH rekomendacijos, remiantis \u012fver\u00adtinta VTE rizika.<\/p>\n<p class=\"Pa15\" style=\"text-align: justify;\"><strong>Tromboprofilaktika nechirurginiams ligoniams <\/strong><\/p>\n<p class=\"Default\" style=\"text-align: justify;\">VTE profilaktikos nauda \u012frodyta klinikiniais ty\u00adrimais chirurgini\u0173 skyri\u0173 pacientams. Ta\u010diau esama vos keletas klinikini\u0173 tyrim\u0173, kuriuose dalyvavo te\u00adrapini\u0173 skyri\u0173 ir ambulatori\u0161kai gydomi ligoniai. Statistiniai duomenys rodo, kad net 50\u201370 proc. simptomin\u0117s VTE ir 70\u201380 proc. mirtin\u0173 <a href=\"https:\/\/pasveik.lt\/lt\/ligos-ir-sindromai\/pate\/43890\">PATE<\/a> pa\u00adsitaiko b\u016btent hospitalizuotiems terapiniams ligo\u00adniams. Autopsijos rezultatai \u0161iuos duomenis patvir\u00adtina \u2013 75 proc. pacient\u0173, kurie mir\u0117 ligonin\u0117je d\u0117l<\/p>\n<p style=\"text-align: justify;\"><a href=\"https:\/\/pasveik.lt\/lt\/ligos-ir-sindromai\/pate\/43890\">PATE<\/a>, pastaruoju metu nebuvo operuoti. D\u0117l \u016bmios ligos guldomiems \u012f ligonin\u0119 pacientams nustatoma 8 kartus didesn\u0117 VTE santykin\u0117 rizika. Hospitalizuo\u00adtiems d\u0117l \u016bmaus miokardo infarkto, insulto, infek\u00adcij\u0173, u\u017edegimin\u0117s \u017earnyno ligos pacientams gili\u0173j\u0173 ven\u0173 tromboz\u0117s (GVT) rizika yra tokia pati, kaip ir operuojamiems pacientams, t. y. apie 25 proc. Dau\u00adguma terapini\u0173 skyri\u0173 ligoni\u0173 turi daugiau negu 1 VTE rizikos veiksn\u012f, kurie vertinant rizik\u0105 da\u017eniau\u00adsiai sumuojami.<\/p>\n<p style=\"text-align: justify;\"><strong>Tyrimo URGENTV modelis <\/strong><\/p>\n<p style=\"text-align: justify;\">Daugiacentriame stebimajame, epidemiologi\u00adniame tyrime URGENTV duomenys rinkti retro\u00adspektyviai. Tyrime dalyvavo vyresni nei 18 met\u0173 pacientai, kurie buvo i\u0161leisti i\u0161 skubiosios pagalbos skyri\u0173 ir konsultuoti d\u0117l \u016bmios ar l\u0117tines infekcin\u0117s ligos, dusulio, plau\u010di\u0173 ar \u0161irdies ligos. \u012e tyrim\u0105 ne\u012f\u00adtraukti pacientai, kurie, prie\u0161 patenkant \u012f pri\u0117mimo skyri\u0173, jau buvo gydomi antikoaguliantais, alergi\u0161ki ma\u017eos molekulin\u0117s mas\u0117s heparinams (MMMH) ar anamnez\u0117je tur\u0117j\u0119 heparino sukelt\u0105 trombocitopeni\u00adj\u0105, bei pacientai, kuriems per pastaruosius 3 m\u0117ne\u00adsius buvo pasirei\u0161k\u0119s <a href=\"https:\/\/pasveik.lt\/lt\/ligos-ir-sindromai\/kraujavimas\/43826\">kraujavimas<\/a> i\u0161 vir\u0161utin\u0117s vir\u0161\u00adkinimo trakto dalies, sergantys kepen\u0173 nepakanka\u00admumu ar turintys kre\u0161\u0117jimo sistemos sutrikim\u0173, di\u00addinan\u010di\u0173 kraujavimo rizik\u0105.<\/p>\n<p style=\"text-align: justify;\">Nepriklausomi kintamieji kiekvienam pacien\u00adtui buvo: 1) demografiniai (am\u017eius, lytis, k\u016bno svoris, \u016bgis, k\u016bno mas\u0117s indeksas); 2) ligonin\u0117s tipas (privati ar vie\u0161oji) ir siuntusi \u012fstai\u00adga (i\u0161 nam\u0173, greitoji pagalba, pirmin\u0117s sveikatos prie\u017ei\u016bros \u012fstaiga, kita ligonin\u0117); 3) gretutin\u0117s ligos (cukrinis diabetas, hiperten\u00adzija, dislipidemija, <a href=\"https:\/\/pasveik.lt\/lt\/ligos-ir-sindromai\/aritmija\/4462\">aritmija<\/a>, <a href=\"https:\/\/pasveik.lt\/lt\/ligos-ir-sindromai\/isemine-sirdies-liga\/4518\">i\u0161emin\u0117 \u0161irdies liga<\/a>, kolitas, kepen\u0173 ligos, inkst\u0173 funkcijos nepakankamumas, neurodegeneracin\u0117s ligos, cerebrovaskulin\u0117s ligos); 4) rizikos \u012fvertinimas ir tromboprofilaktikos re\u00adkomendacijos: rizika \u012fvertinta pagal 2007 met\u0173 PRETEMED rekomendacij\u0173 skal\u0119 (13). Ja remiantis, pacientai buvo suskirstyti \u012f ma\u017eos, vidutin\u0117s ir didel\u0117s rizikos grupes. Vidutin\u0117s ir didel\u0117s rizikos pacientams rekomenduojama profilaktika MMMH.<\/p>\n<p style=\"text-align: justify;\">M\u0117nes\u012f po i\u0161leidimo i\u0161 pri\u0117mimo skyriaus pa\u00adcientai buvo stebimi \u2013 fiksuojamos visos GVT ir <a href=\"https:\/\/pasveik.lt\/lt\/ligos-ir-sindromai\/pate\/43890\">PATE<\/a> diagnoz\u0117s.<\/p>\n<p style=\"text-align: justify;\"><strong>Tyrimo URGENTV rezultatai <\/strong><\/p>\n<p style=\"text-align: justify;\">Tyrime dalyvavo 2 280 pacient\u0173, kurie atitiko visus kriterijus. I\u0161 j\u0173 1 850 (81,1 proc) priskirti vi\u00addutin\u0117s ir didel\u0117s trombini\u0173 embolij\u0173 rizikos gru\u00adpei. Da\u017eniausi rizikos veiksniai buvo \u016bmi infek\u00adcija (22,3 proc.), III funkcin\u0117s klas\u0117s \u0161irdies nepa\u00adkankamumas (16,5 proc.), navikai (18,3 proc.) ir pa\u016bm\u0117jusi <a href=\"https:\/\/pasveik.lt\/lt\/ligos-ir-sindromai\/letine-obstrukcine-plauciu-liga\/4463\">l\u0117tin\u0117 obstrukcin\u0117 plau\u010di\u0173 liga<\/a> (LOPL) (20,2 proc.). Taip pat da\u017enai pasitaikydavo ir toki\u0173 rizikos veiksni\u0173, kaip cukrinis diabetas, antidepre\u00adsant\u0173 vartojimas, vyresnis am\u017eius (daugiau nei 60 met\u0173), r\u016bkymas, <a href=\"https:\/\/pasveik.lt\/lt\/ligos-ir-sindromai\/nutukimas\/4355\">nutukimas<\/a> ir negalia. Farmakolo\u00adgin\u0117 tromboprofilaktika MMMH skirta 57,9 proc. \u0161i\u0173 pacient\u0173, turin\u010di\u0173 vidutin\u0119 ir didel\u0119 trombini\u0173 embolij\u0173 rizik\u0105. Jos trukm\u0117 buvo 16,4\u00b114,3 die\u00adnos. Ta\u010diau net 42,1 proc. \u0161i\u0173 pacient\u0173 trombopro\u00adfilaktinis gydymas, i\u0161ra\u0161ant i\u0161 skubiosios pagalbos skyriaus, nebuvo paskirtas. Atlikus rizikos veiks\u00adni\u0173 statistin\u0119 analiz\u0119, nustatyta, kad veiksniai, ne\u00adpriklausomai susij\u0119 su profilaktinio tromb\u0173 gydymo nepaskyrimu, buvo: nenumatytas mobilumo suma\u00ad\u017e\u0117jimas, neurodegeneracin\u0117 liga anamnez\u0117je, gydy\u00admo skubiosios pagalbos skyriuje trukm\u0117 &gt;12 val. ir vyresnis am\u017eius.<\/p>\n<p style=\"text-align: justify;\">Po 1 m\u0117nesio nuo i\u0161leidimo i\u0161 pri\u0117mimo ir sku\u00adbiosios pagalbos skyriaus \u012fvertinti tik 887 pacien\u00adtai (47,9 proc.) i\u0161 1 850, kuriems nustatyta vidutin\u0117 ir didel\u0117 trombin\u0117s embolijos rizika. I\u0161 \u0161i\u0173 pacient\u0173 28 (3 proc.) persirgo VTE (19 DVT atvej\u0173 ir 9 <a href=\"https:\/\/pasveik.lt\/lt\/ligos-ir-sindromai\/pate\/43890\">PATE<\/a> atvejai). I\u0161 \u0161i\u0173 28 pacient\u0173, i\u0161leist\u0173 i\u0161 skubiosios pa\u00adgalbos skyriaus, 19 pacient\u0173 (67,9 proc.) nebuvo paskirtas tromboprofilaktinis gydymas (<em>1 lentel\u0117<\/em>).<\/p>\n<p><img decoding=\"async\" src=\"data:image\/jpeg;base64,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\n<\/p>\n","protected":false},"excerpt":{"rendered":"<p style=\"text-align: justify;\">Europoje i\u0161tyrus venini\u0173 trombini\u0173 embolij\u0173 (VTE) da\u017en\u012f hospitalizuotiems ir gydomiems am\u00adbulatori\u0161kai pacientams, nustatyta, kad per metus ji pasitaiko 148 i\u0161 100 t\u016bkst. pacient\u0173 (atitinkamai 83 atvejai hospitalizuotiems ir 65 atvejai gydomiems ambulatori\u0161kai pacientams) (1). Taip pat paai\u0161k\u0117jo, kad net 71 proc. ligonin\u0117je gydom\u0173 pacient\u0173, ku\u00adriems diagnozuota VTE, mir\u0117 (1).<\/p>\n","protected":false},"author":1,"featured_media":7827,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[27313],"tags":[400,267,197,803,243,791,157,415,125,3737],"site":[],"post_item_type":[27345],"class_list":["post-7826","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-gydymo-naujienos","tag-diabetas","tag-diagnozuota","tag-kraujavimas","tag-kraujavimo-rizika","tag-ligonines","tag-mases","tag-nutukimas","tag-profilaktika","tag-rukymas","tag-tromboprofilaktika"],"acf":{"post_sites":false},"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/posts\/7826","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/comments?post=7826"}],"version-history":[{"count":0,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/posts\/7826\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/media\/7827"}],"wp:attachment":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/media?parent=7826"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/categories?post=7826"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/tags?post=7826"},{"taxonomy":"site","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/site?post=7826"},{"taxonomy":"post_item_type","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/post_item_type?post=7826"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}